Craniopharyngioma Drug Discovery Service
Creative Biolabs is an experienced leading service provider in the field of life science. Our scientists focus on neuroscience research and have developed a sophisticated platform, that offers global researchers reliable one-stop solutions for craniopharyngioma studies.
Craniopharyngiomas are rare extra-axial epithelial neoplasms in the central nervous system, which are generally classified into two predominant histological subtypes, adamantinomatous and papillary craniopharyngiomas. They are slow-growing benign tumors that extend into the critical cranial structures, including the sella and parasellar region. Then they adhere to and invade vascular and cortical structures, which lead to dysfunctions in the pituitary, hypothalamus, and optic nerve and, in severe cases, obstructive hydrocephalus. Currently, there exist no effective therapeutic agents for the treatment of craniopharyngiomas. With advanced technologies and tools, Creative Biolabs is committed to providing a full range of services to meet your research and development requirements in craniopharyngioma mechanism of action (MoA) studies and drug discovery.
Mechanism of Action Studies of Craniopharyngioma
The pathogenesis of craniopharyngiomas is the result of multiple genomic alterations on chromosomes 2 and 12, including dysregulation of DNA methylation and repair patterns, loss of tumor suppressor genes, and activation of oncogenes. Adamantinomatous craniopharyngiomas are mostly found in childhood, while papillary craniopharyngiomas occur exclusively in adults. Adamantinomatous craniopharyngiomas arise from ectopic embryonic remnants of Rathke's pouch, which have intimate interaction with the mutations of b-catenin encoded by the CTNNB1 gene. The expression of mutant b-catenin leads to accumulations in the nucleus and cytosol that activates the Wnt signaling pathway and thus causes tumorigenesis. The underlying mechanism of papillary craniopharyngiomas is awaited to be explained. Our neural scientists are prepared to answer questions you may have when studying craniopharyngioma and provide you with suggestions for your research projects.
Fig.1 Clinical and histopathological characteristics of adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP). (Müller, 2019)
Craniopharyngioma Solutions at Creative Biolabs
Current treatment for brain tumor craniopharyngiomas generally uses the surgical removal of the tumor via orbitozygomatic craniotomy. This treatment regimen has a high surgical risk as it requires access to the skull base. Postoperative management may also recommend hormone replacement therapy with or without stereotactic radiotherapy. In addition, treatments for craniopharyngiomas also include cyst drainage, intracystic therapy with interferon-α, chemotherapy, radiotherapy, and immunotherapy, which depends on the tumor size, location, extension, and potential toxicity. Novel treatments with low surgical risks need to be explored. With years of experience, Creative Biolabs provides comprehensive in vitro, in vivo, and ex vivo services as well as discovery and development services for craniopharyngioma studies. We provide dependable cell culture models and animal models to meet your research and development demands. The pathogenesis of both subtypes of craniopharyngiomas still needs to be addressed. For further MoA studies and drug discovery and development, a full range of discovery services is available at Creative Biolabs. More details about our platform and services for translational research and integrated research in craniopharyngiomas are demonstrated as follows.
To customize your preclinical craniopharyngioma drug discovery projects, please directly contact us for more information.
Reference
- Müller, H.L.; et al. Craniopharyngioma. Nature Reviews Disease Primers. 2019, 5: 75.
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-TREM2 BBB Shuttle Antibody (NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- iNeuMab™ Anti-CD32b Antibody (NRP-0422-P1803) (Cat#: NRP-0422-P1803)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- iNeuMab™ Anti-TREM2 Antibody (NRP-0422-P792) (Cat#: NRP-0422-P792)
- iNeuMab™ Anti-EPHB2 Antibody (NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) (Cat#: NCL-2103-P49)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- iNeu™ Human Neural Stem Cell Line (Cat#: NCL200552ZP)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Mouse Glioma Cell Line GL-261-Luc (Cat#: NCL-2108P06)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)